NURO NeuroMetrix Inc.

NeuroMetrix Announces That Quell Is Featured in Huffington’s New Thrive Global Platform

NeuroMetrix, Inc. (Nasdaq: NURO, NUROW) announced today that its Quell® Wearable Pain Relief Technology™ is featured in the new Thrive Global commerce platform, including the online store at ThriveGlobal.com and Retail Pop Up Experience in New York City from December 1st to January 15th.

Thrive Global’s commerce platform offers a curated selection of the latest and best technology and products for well-being and performance. Along with its scientific advisory board and academic partners, Thrive Global’s team vetted hundreds of the latest health and well-being products, services and technologies, and are showcasing the ones that meet their standards for quality, impact and behavior change. This includes best-in-class leaders in the health and well-being space and emerging forward thinking technologies.

“We are thrilled to partner with Thrive Global, Arianna Huffington’s groundbreaking venture to offer Quell to consumers looking for the latest innovations in health and wellbeing,” said Frank McGillin, NeuroMetrix Senior Vice President & Chief Commercial Officer. “We align strongly with Thrive Global’s mission and are excited to be a part of this exciting new concept.”

Thrive Global’s Founder Arianna Huffington said, “We are a company deeply rooted in science and dedicated to helping people go from knowing what to do to bring more well-being into their lives to actually doing it. I'm so excited about the amazing collection of products, services and technologies we’re featuring at Thrive Global that will help people improve their well-being and productivity and lead healthier and more joyful lives.”

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can start, stop, and adjust therapy discreetly via the optional Quell Relief app. Quell also offers advanced sleep tracking that provides feedback on eight dimensions of sleep including sleep duration, quality, body position, time out of bed, and repetitive leg movements throughout the night. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About Thrive Global

Thrive Global was founded by Arianna Huffington with the mission to end the stress and burnout epidemic by offering companies and individuals sustainable, science-based solutions to enhance both well-being and performance. The Thrive Global Store is the answer to the growing consumer demand for a trusted place to discover the best in health and well-being, curated for you. In collaboration with its scientific and academic partners, Thrive Global has vetted hundreds of the latest health and well-being products, services and technologies.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.

EN
13/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NeuroMetrix Inc.

Neurometrix Inc: 1 director

A director at Neurometrix Inc sold 20,000 shares at 13.560USD and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

 PRESS RELEASE

NeuroMetrix Announces Issuance of New U.S. Patent for Quell Wearable T...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,827,420. The patent covers novel technology that enhances Quell® device usability by improving performance for users that maintain an active lifestyle. "We are pleased to have received this latest patent, which expands the Quell intellectual property portfolio. The ability to easily and intuitively interact with the Quell device is important to Quell users as daily use is co...

 PRESS RELEASE

NeuroMetrix Closes $3.5 Million Equity Offering

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ: NURO) today closed a $3.5 million private placement of 3,500 shares of Series F convertible preferred stock at a price of $1,000 per share that are convertible into 1,330,798 shares of common stock at a conversion price of $2.63 per share. The Company’s common stock closed on October 30, 2017 at $1.80 per share. Proceeds of the offering will be used for commercialization of Quell®, the Company's over-the-counter wearable device for relief of chronic pain and for general work...

 PRESS RELEASE

NeuroMetrix Reports Q3 2017 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended September 30, 2017. The Company develops and markets novel therapies, based on neurostimulation and digital medicine, for chronic health conditions. The Company’s primary product is Quell®, which is an over-the-counter wearable neurostimulation device for treating chronic pain. The Company also has a diagnostic business based on its DPNCheck® product, which is a point-of-care test that pro...

 PRESS RELEASE

NeuroMetrix, Inc. Announces Date for 2017 Third Quarter Financial Resu...

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) announced today that it plans to issue its 2017 third quarter financial results before the opening of the market on Thursday October 19, 2017. The Company will host a conference call at 8:00 a.m., Eastern Time on October 19, 2017 to discuss its financial results as well as business developments affecting the Company. The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 84863406. Internationally, the co...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch